Formed recently as a spin-out company of GammaDelta Therapeutics, Adaptate’s technology aims to modulate γδ T-cell activity using therapeutic antibodies, with the potential to trigger immune responses against cancer.
Co-funded by Takeda, the spin-out company plans to further develop these antibody targets and advance them into clinical studies.
On its side, Iontas’ platform enables the construction of large libraries of stable cell lines, while at the same time it has the potential to address challenges that occur at early stages of development, according to the company.
The collaborative agreement will see Adaptate work on Iontas’ platform with the aim to select high affinity antibodies based on criteria including function, stability, and expression and transition them through chemistry, manufacturing and controls (CMC) processes.
John McCafferty, Iontas’ CEO commented that the collaboration is a ‘validation’ of the company’s ‘Mammalian Display’ platform, which is expected to facilitate the manufacture of antibody-based therapeutics by reducing the risk of delays and product failure through “detecting and avoiding problematic clones at the outset.”
“Our aim is to ensure the right lead is selected first time, every time,” McCafferty noted.
CEO of Adaptate, Natalie Mount, stated that the company anticipates the collaborative work to accelerate entry to the clinic for Adaptate’s oncology candidates.
